Head-To-Head Survey: FibroBiologics (NASDAQ:FBLG) versus Edesa Biotech (NASDAQ:EDSA)

FibroBiologics (NASDAQ:FBLG) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, earnings, dividends and institutional ownership.

Profitability

This table compares FibroBiologics and Edesa Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
FibroBiologics	N/A	N/A	N/A
Edesa Biotech	N/A	-137.95%	-97.48%

Insider and Institutional Ownership

5.5% of Edesa Biotech shares are held by institutional investors. 25.0% of Edesa Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares FibroBiologics and Edesa Biotech”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FibroBiologics	N/A	N/A	-$16.49 million	N/A	N/A
Edesa Biotech	N/A	N/A	-$8.37 million	N/A	N/A

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for FibroBiologics and Edesa Biotech, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FibroBiologics	0	0	1	1	3.50
Edesa Biotech	0	0	2	0	3.00

FibroBiologics currently has a consensus target price of $12.00, suggesting a potential upside of 322.54%. Edesa Biotech has a consensus target price of $39.00, suggesting a potential upside of 815.49%. Given Edesa Biotech’s higher probable upside, analysts plainly believe Edesa Biotech is more favorable than FibroBiologics.

Summary

Edesa Biotech beats FibroBiologics on 5 of the 9 factors compared between the two stocks.

About FibroBiologics

FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

About Edesa Biotech

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.